Loading...
XSHE002275
Market cap1.02bUSD
Jan 14, Last price  
13.46CNY
1D
2.20%
1Q
-8.44%
Jan 2017
-26.73%
IPO
-47.09%
Name

Guilin Sanjin Pharmaceutical Co.

Chart & Performance

D1W1MN
XSHE:002275 chart
P/E
17.69
P/S
3.43
EPS
0.76
Div Yield, %
5.74%
Shrs. gr., 5y
-0.18%
Rev. gr., 5y
6.50%
Revenues
2.17b
+10.81%
797,851,762893,048,449986,157,9501,110,828,532983,460,3951,161,780,7611,311,546,6411,452,636,2411,466,351,7721,371,821,2071,525,223,9961,616,016,1871,584,673,4311,640,423,7311,566,484,6731,741,224,5521,959,732,8452,171,603,363
Net income
421m
+27.85%
194,803,906249,177,709273,726,598307,314,926258,757,964291,953,755331,151,947420,267,879444,866,401376,672,835393,660,036464,402,333413,346,104392,142,681277,020,898343,718,942329,526,519421,298,789
CFO
549m
+3.89%
217,665,767164,390,698190,965,906363,289,565285,487,714341,049,794302,589,346314,159,410396,529,896398,495,405536,851,083387,823,159551,726,197468,285,131597,991,408410,241,541528,666,938549,245,571
Dividend
May 29, 20240.3 CNY/sh
Earnings
May 16, 2025

Profile

Guilin Sanjin Pharmaceutical Co., Ltd. engages in the research, production, and sale of traditional Chinese and natural medicines in China. The company primarily offers Guilin watermelon frost and lozenge, and Sanjin tablets under the Chinese TCM brand; and Naomaitai capsules, etc. It also produces TCM preparations. The company was founded in 1967 and is headquartered in Guilin, China. Guilin Sanjin Pharmaceutical Co., Ltd. operates as a subsidiary of Guilin SanJin Group Co.,Ltd.
URL
http://www.sanjin.com.cn
IPO date
Jul 10, 2009
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
2,171,603
10.81%
1,959,733
12.55%
Cost of revenue
1,547,345
1,386,751
Unusual Expense (Income)
NOPBT
624,258
572,982
NOPBT Margin
28.75%
29.24%
Operating Taxes
96,985
116,653
Tax Rate
15.54%
20.36%
NOPAT
527,273
456,329
Net income
421,299
27.85%
329,527
-4.13%
Dividends
(427,773)
(528,812)
Dividend yield
5.05%
6.81%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
274,201
259,397
Long-term debt
195,824
284,934
Deferred revenue
89,043
97,846
Other long-term liabilities
1,337
1
Net debt
(947,057)
(882,616)
Cash flow
Cash from operating activities
549,246
528,667
CAPEX
Cash from investing activities
(94,222)
Cash from financing activities
(361,568)
FCF
621,588
479,744
Balance
Cash
1,362,794
1,426,946
Long term investments
54,287
Excess cash
1,308,501
1,328,960
Stockholders' equity
2,248,444
2,244,815
Invested Capital
2,007,914
1,954,940
ROIC
26.61%
22.41%
ROCE
18.82%
17.45%
EV
Common stock shares outstanding
585,137
587,569
Price
14.49
9.61%
13.22
-21.82%
Market cap
8,478,638
9.15%
7,767,657
-20.15%
EV
7,531,582
6,885,041
EBITDA
739,377
687,814
EV/EBITDA
10.19
10.01
Interest
16,355
20,235
Interest/NOPBT
2.62%
3.53%